Submitted to: Research Workers in Animal Diseases Conference Proceedings
Publication Type: Abstract Only
Publication Acceptance Date: November 10, 2002
Publication Date: November 10, 2002
Technical Abstract: Recombinant human adenovirus (rAd) vectored vaccines for pseudorabies (PRV) have been shown to prime immunity in neonatal piglets and to overcome interference by maternal-derived anti-PRV antibodies (J. Gen. Virol. 78:3303-10, 1997). Similarly, replication-incompetent adenoviruses containing either the H3 hemagglutinnin gene or the nucleoprotein gene of swine influenza virus H3N2 were constructed and were used to inoculate weaned pigs by a single intramuscular inoculation. The hemagglutination inhibition (HI) antibody response to SIV was measured as an indication of exposure to the rAd5-SIV vaccine. Sentinnel pigs were commingled with each group of vaccinates for 5 weeks to determine the safety of the vaccine in terms of animal to animal spread. Five weeks after vaccination the pigs were challenged with a different virulent SIV. The potency of the vaccination protocol was demonstrated by a reduction in clinical signs, by the elimination of nasal shedding of the challenge virus, and by the elimination of SIV-induced lung lesions. These rAd5-SIV vaccines could provide priming of the immune system to overcome the effects of maternal- derived antibody which interferes with conventional SIV vaccines. Acknowledgments: Part of this research was funded by a grant from the National Pork Board, Des Moines, Iowa.